Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

<p>Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Ernesto Gargiulo (15134961) (author)
Andere auteurs:	Elodie Viry (15134964) (author), Pablo Elías Morande (15134967) (author), Anne Largeot (15134970) (author), Susanne Gonder (15134973) (author), Feng Xian (15134976) (author), Nikolaos Ioannou (15134979) (author), Mohaned Benzarti (15134982) (author), Felix Bruno Kleine Borgmann (15134985) (author), Michel Mittelbronn (15134988) (author), Gunnar Dittmar (15134991) (author), Petr V. Nazarov (15134994) (author), Johannes Meiser (15134997) (author), Basile Stamatopoulos (15135000) (author), Alan G. Ramsay (15021857) (author), Etienne Moussay (15135003) (author), Jérôme Paggetti (15135006) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Tumor Biology Immuno-oncology Methods and Technology Hematological Cancers Leukemias Lymphomas Immunology T cell exhaustion Tumor resistance to immune response Preclinical Models Animal models of cancer Tumor Microenvironment Immune cells and the microenvironment
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
door: Ernesto Gargiulo (15134961)
Gepubliceerd in: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
door: Andrew Nguyen (17142197)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
door: Shih-Shih Chen (15314296)
Gepubliceerd in: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
door: Yu Chen (1234761)
Gepubliceerd in: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
door: Yu Chen (1234761)
Gepubliceerd in: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
door: Yu Chen (1234761)
Gepubliceerd in: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
door: Yu Chen (1234761)
Gepubliceerd in: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
door: Erika Y. Faraoni (14844897)
Gepubliceerd in: (2025)

Table S1 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S2 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S3 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S4 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S5 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S6 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Table S7 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
door: Fanfan Fan (16799646)
Gepubliceerd in: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
door: Isha Mondal (16721699)
Gepubliceerd in: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
door: Dahihm Kim (16546203)
Gepubliceerd in: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
door: Dahihm Kim (16546203)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_dh68s1apjrcmojhi8vukb3fgp5